SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-19-129402
Filing Date
2019-04-30
Accepted
2019-04-30 16:19:55
Documents
10
Effectiveness Date
2019-04-30

Document Format Files

Seq Description Document Type Size
1 DEFA14A d685689ddefa14a.htm DEFA14A 30540
2 GRAPHIC g685689dsp002d.jpg GRAPHIC 3932
3 GRAPHIC g685689dsp002i.jpg GRAPHIC 853
4 GRAPHIC g685689g13x38.jpg GRAPHIC 1358
5 GRAPHIC g685689g23r76.jpg GRAPHIC 2781
6 GRAPHIC g685689g65o14.jpg GRAPHIC 13519
7 GRAPHIC g685689g66c92.jpg GRAPHIC 1656
8 GRAPHIC g685689g73y54.jpg GRAPHIC 844
9 GRAPHIC g685689g90g29.jpg GRAPHIC 1373
10 GRAPHIC g685689g93p28.jpg GRAPHIC 21695
  Complete submission text file 0001193125-19-129402.txt   99044
Mailing Address 430 EAST 29TH STREET NEW YORK NY 10016
Business Address 430 EAST 29TH STREET NEW YORK NY 10016 212-923-3344
Intra-Cellular Therapies, Inc. (Filer) CIK: 0001567514 (see all company filings)

IRS No.: 364742850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-36274 | Film No.: 19782033
SIC: 2834 Pharmaceutical Preparations